Current Problems in Cancer: Case Reports is a prominent scholarly journal published by Elsevier, focusing on critical case reports within the field of oncology. Since its transition to Open Access in 2020, it has enhanced accessibility for researchers and healthcare professionals seeking to share and discuss unique clinical scenarios and insights that advance cancer treatment and patient care. Operating from the United States, this journal aims to address the important and often intricate challenges faced in oncology, facilitating a platform for knowledge exchange and the exploration of new perspectives in cancer management. Despite its current Q4 category ranking in the 2023 oncology category of Scopus with a rank of #359/404, its goal is to enrich the academic discourse by featuring diverse case reports and promoting evidence-based practices. As the journal evolves from 2021 to 2024, it seeks to impact the field by inviting researchers, professionals, and students to contribute their findings, ultimately fostering a collaborative environment for tackling the complexities of cancer.

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Renal Replacement Therapy is an esteemed open-access journal published by BMC, dedicated to advancing the field of nephrology, transplantation, and urology. Established in 2015, the journal aims to disseminate high-quality research findings to enhance the understanding and management of kidney-related diseases and therapies. Renal Replacement Therapy is ranked in the third quartile (Q3) in the categories of Nephrology, Transplantation, and Urology as of 2023, reflecting its growing influence and commitment to academic excellence. The journal encourages interdisciplinary study and collaboration, welcoming contributions from researchers, clinicians, and healthcare professionals. With a focus on practical applications and innovative therapies, this journal is instrumental for those seeking the latest insights and advancements in renal replacement strategies. Located in the United Kingdom, the journal strives to provide unparalleled access to critical research, ensuring that its findings are available to a global audience striving to improve patient outcomes in renal health.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Renal Society of Australasia Journal, published by the Renal Society of Australasia, serves as a crucial platform for disseminating cutting-edge research and insights within the fields of nephrology and urology. With its ISSN of 1832-3804, this journal has been continually published since 2011, showcasing the evolving landscape of renal health in Australia and beyond. Despite currently holding a Q4 ranking in both nephrology and urology categories, the journal is committed to supporting the scientific community with rigorous peer-reviewed articles that enhance clinical practice and foster research advancement. As an open access journal, it aims to provide wide visibility and access to researchers, professionals, and students alike, thus promoting knowledge sharing among various stakeholders in renal health. Positioned within a global context, it addresses local health challenges while contributing to the broader discourse in renal sciences, making it an essential resource for those dedicated to improving patient outcomes in this critical area of medicine.

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.

BJU International is a prestigious academic journal specializing in the field of Urology, published by WILEY, one of the leading publishers in scientific literature. With an impressive impact factor and recognized as a Q1 journal in Urology for 2023, it ranks #7 out of 120 in the Scopus Medicine _ Urology category, placing it in the 94th percentile among its peers. Established in 1929 and with converged years from 1994 to 2024, BJU International provides a platform for groundbreaking research, clinical studies, and advancements in urological science. The journal is accessible in both print and online formats, catering to a global audience dedicated to enhancing urological practice and research. By fostering interdisciplinary dialogue and disseminating high-quality studies, BJU International plays a crucial role in advancing knowledge and improving patient care in the field of urology.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.